Arcus Biosciences
RCUS
75 hedge funds and large institutions have $274M invested in Arcus Biosciences in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 10 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
17% more capital invested
Capital invested by funds: $235M → $274M (+$38.8M)
2.8% more ownership
Funds ownership: 56.29% → 59.1% (+2.8%)
0% more funds holding
Funds holding: 75 → 75 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$11.5M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.01M |
| 3 |
BlackRock
New York
|
+$898K |
| 4 |
Two Sigma Investments
New York
|
+$775K |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$725K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$23.1M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$1.72M |
| 3 |
JP Morgan Chase
New York
|
-$362K |
| 4 |
Millennium Management
New York
|
-$316K |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$279K |
RCUS Hedge Fund Activity: Q4 2019 in Review
75 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2019, worth a combined $274M — up 17% from $235M a quarter earlier.
Fund positioning in RCUS was balanced in Q4 2019: 10 funds opened new positions, 10 closed out, 34 added to existing stakes and 15 trimmed.
The largest buyer was Boxer Capital, adding an estimated $11.5M. The largest seller was Wellington Management Group, exiting entirely with an estimated $23.1M sold.
- 75 institutional investors held Arcus Biosciences (RCUS) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $274M of Arcus Biosciences stock for Q4 2019, up 17% quarter-over-quarter.
- 10 funds opened new Arcus Biosciences positions in Q4 2019 and 10 closed out, a net change of 0 holders.
- The largest Arcus Biosciences buyer in Q4 2019 was Boxer Capital, an estimated $11.5M added.
- The largest Arcus Biosciences seller in Q4 2019 was Wellington Management Group, an estimated $23.1M sold.
Based on aggregated 13F filings for Q4 2019.